Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells

Nitric Oxide - Biology and Chemistry

Volumn 19, Issue 2, 2008, Pages 184-191

  Badireenath Konkimalla, V ^a   Blunder, Martina ^b   Korn, Bernhard ^a   Soomro, Shahid A ^c   Jansen, Herwig ^c   Chang, Wonsuk ^d   Posner, Gary H ^d   Bauer, Rudolf ^b   Efferth, Thomas ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

^c Dafra Pharma nv   (Belgium)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Artemisinin; Microarray; Nitric oxide; Pharmacogenomics; Pharmacognosy; Traditional Chinese medicine

Indexed keywords

ARTEMISIA ANNUA EXTRACT; ARTEMISININ DERIVATIVE; ARTESUNATE; CATENIN; CYCLIC AMP; DF 31; DF 36; DF 37 2; ENDOPEROXIDE; GHP AJM 3 23; ME 20050015; ME 20050016; MESSENGER RNA; NITRIC OXIDE; WNT PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTEMISIA ANNUA; ARTICLE; CELL INTERACTION; CHINESE MEDICINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; GENE EXPRESSION; IC 50; INHIBITION KINETICS; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PHARMACOGNOSY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARTEMISININS; CELL COMMUNICATION; CELL DEATH; CELL LINE; GENE EXPRESSION PROFILING; MACROPHAGES; MICE; NITRIC OXIDE; PEROXIDES; SIGNAL TRANSDUCTION;

ARTEMISIA ANNUA; ARTESUNATE;

EID: 47049126119     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.04.008     Document Type: Article

References (58)

1. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 343 (1994) 1199-1206
2. Lechner M., Lirk P., and Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol. 15 (2005) 277-289
3. Sawa T., and Ohshima H. Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 14 (2006) 91-100
4. Murakami A., and Ohigashi H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int. J. Cancer 121 (2007) 2357-2363
5. Perwez Hussain S., and Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121 (2007) 2373-2380
6. Wink D.A., Kasprzak K.S., Maragos C.M., Elespuru R.K., Misra M., Dunams T.M., Cebula T.A., Koch W.H., Andrews A.W., Allen J.S., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254 (1991) 1001-1003
7. Schmutte C., Rideout III W.M., Shen J.C., and Jones P.A. Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double-stranded DNA. Carcinogenesis 15 (1994) 2899-2903
8. Felley-Bosco E. Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis Rev. 17 (1998) 25-37
9. Li C.Q., Trudel L.J., and Wogan G.N. Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53. Proc. Natl. Acad. Sci. USA 99 (2002) 10364-10369
10. Ridnour L.A., Thomas D.D., Donzelli S., Espey M.G., Roberts D.D., Wink D.A., and Isenberg J.S. The biphasic nature of nitric oxide responses in tumor biology. Antioxid. Redox Signal. 8 (2006) 1329-1337
11. Bentz B.G., Haines III G.K., Lingen M.W., Pelzer H.J., Hanson D.G., and Radosevich J.A. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann. Otol. Rhinol. Laryngol. 108 (1999) 781-787
12. Tanaka H., Kijima H., Tokunaga T., Tajima T., Himeno S., Kenmochi T., Oshiba G., Kise Y., Nishi T., Chino O., Shimada H., Machimura T., Tanaka M., and Makuuchi H. Frequent expression of inducible nitric oxide synthase in esophageal squamous cell carcinomas. Int. J. Oncol. 14 (1999) 1069-1073
13. Jang T.J., and Kim D.K. Inducible nitric oxide synthase expression of tumor and stromal cells is associated with the progression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Cancer Lett. 182 (2002) 121-126
14. Franco L., Doria D., Bertazzoni E., Benini A., and Bassi C. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat. 73 (2004) 51-58
15. Speranza L., De Lutiis M.A., Shaik Y.B., Felaco M., Patruno A., Tetè A., Mastrangelo F., Madhappan B., Castellani M.L., Conti F., Vecchiet J., Theoharides T.C., Conti P., and Grilli A. Localization and activity of iNOS in normal human lung tissue and lung cancer tissue. Int. J. Biol. Markers 22 (2007) 226-231
16. Chen H.H., Su W.C., Chou C.Y., Guo H.R., Ho S.Y., Que J., and Lee W.Y. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 63 (2005) 1093-1100
17. Li L.G., and Xu H.N. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J. Gastroenterol. 11 (2005) 2539-2544
18. Wang L., Shi G.G., Yao J.C., Gong W., Wei D., Wu T.T., Ajani J.A., Huang S., and Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer 8 (2005) 18-28
19. Ekmekcioglu S., Ellerhorst J.A., Prieto V.G., Johnson M.M., Broemeling L.D., and Grimm E.A. Tumor iNOS predicts poor survival for stage III melanoma patients. Int. J. Cancer 119 (2006) 861-866
20. Badn W., Hegardt P., Fellert M.A., Darabi A., Esbjörnsson M., Smith K.E., Janelidze S., Salford L.G., Visse E., and Siesjö P. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. Scand. J. Immunol. 65 (2007) 289-297
21. Frederiksen L.J., Sullivan R., Maxwell L.R., Macdonald-Goodfellow S.K., Adams M.A., Bennett B.M., Siemens D.R., and Graham C.H. Chemosensitization of cancer in vitro and in vivo by nitric oxide signalling. Clin. Cancer Res. 13 (2007) 2199-2206
22. Hirst D.G., and Robson T. Nitrosative stress in cancer therapy. Front Biosci. 12 (2007) 3406-3418
23. Efferth T., Rücker G., Falkenberg M., Manns D., Olbrich A., Fabry U., and Osieka R. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 46 (1996) 196-200
24. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., and Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 18 (2001) 767-773
25. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 8 (2005) 85-97
26. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 7 (2006) 407-421
27. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med. 73 (2007) 299-309
28. Efferth T., Benakis A., Romero M.R., Tomicic M., Rauh R., Steinbach D., Häfer R., Stamminger T., Oesch F., Kaina B., and Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 37 (2004) 998-1009
29. Lai H., Sasaki T., and Singh N.P. Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. Expert Opin. Ther. Targets 9 (2005) 995-1007
30. Kelter G., Steinbach D., Konkimalla V.B., Tahara T., Taketani S., Fiebig H.H., and Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE 2 (2007) e798
31. Efferth T., Olbrich A., and Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 64 (2002) 617-623
32. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., Hengstler J.G., Halatsch M.E., Volm M., Tew K.D., Ross D.D., and Funk J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 64 (2003) 382-394
33. Anfosso L., Efferth T., Albini A., and Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 6 (2006) 269-278
34. Efferth T., Briehl M.M., and Tome M.E. Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. 23 (2003) 1231-1235
35. Efferth T., and Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. 68 (2004) 3-10
36. Efferth T., Davey M., Olbrich A., Rücker G., Gebhart E., and Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 28 (2002) 160-168
37. Dell'Eva R., Pfeffer U., Vené R., Anfosso L., Forlani A., Albini A., and Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharmacol. 68 (2004) 2359-2366
38. Berger T.G., Dieckmann D., Efferth T., Schultz E.S., Funk J.O., Baur A., and Schuler G. Artesunate in the treatment of metastatic uveal melanoma--first experiences. Oncol. Rep. 14 (2005) 1599-1603
39. Alagbala A.A., McRiner A.J., Bortsnik K., Labonte T., Chang W., D'Angelo J., Posner G.H., and Foster B.A. Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines. J. Med. Chem. 49 (2006) 7836-7842
40. Baer H.P., Schmidt K., Mayer B., and Kukovetz W.R. Pentamidine does not interfere with nitrite formation in activated RAW 264.7 macrophages but inhibits constitutive brain nitric oxide synthase. Life Sci. 57 (1995) 1973-1980
41. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., and Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity using human and other tumor cell lines. Cancer Res. 48 (1988) 4827-4833
42. Eberwine J., Yeh H., Miyashiro K., Cao Y., Nair S., Finnell R., Zettel M., and Coleman P. Analysis of gene expression in single live neurons. Proc. Natl. Acad. Sci. USA 89 (1992) 3010-3014
43. Severina I.S., Pyatakova N.V., Bussygina O.G., Mikhailitsyn F.S., and Khropov Y.V. Inhibition of nitric oxide-dependent activation of soluble guanylyl cyclase by the antimalarial drug, artemisinin. Eur. J. Pharmacol. 438 (2002) 69-73
44. Aldieri E., Atragene D., Bergandi L., Riganti C., Costamagna C., Bosia A., and Ghigo D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett. 552 (2003) 141-144
45. Azizzadeh B., Yip H.T., Blackwell K.E., Horvath S., Calcaterra T.C., Buga G.M., Ignarro L.J., and Wang M.B. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope 111 (2001) 1896-1900
46. Konovalova N.P., Goncharova S.A., Volkova L.M., Rajewskaya T.A., Eremenko L.T., and Korolev A.M. Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide 8 (2003) 59-64
47. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D., and Bosia A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 65 (2005) 516-525
48. Bratasz A., Weir N.M., Parinandi N.L., Zweier J.L., Sridhar R., Ignarro L.J., and Kuppusamy P. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc. Natl. Acad. Sci. USA 103 (2006) 3914-3919
49. Chanvorachote P., Nimmannit U., Stehlik C., Wang L., Jiang B.H., Ongpipatanakul B., and Rojanasakul Y. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res. 66 (2006) 6353-6360
50. Matthews N.E., Adams M.A., Maxwell L.R., Gofton T.E., and Graham C.H. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J. Natl. Cancer Inst. 93 (2001) 1879-1885
51. Wang Y., and Aggarwal S.K. Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity. Anticancer Drugs 8 (1997) 853-858
52. Xu W., Liu L., Smith G.C., and Charles G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat. Cell Biol. 2 (2000) 339-345
53. Saleh S., and El-Demerdash E. Protective effects of l-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin. Pharmacol. Toxicol. 97 (2005) 91-97
54. Chirino Y.I., Trujillo J., Sánchez-González D.J., Martínez-Martínez C.M., Cruz C., Bobadilla N.A., and Pedraza-Chaverri J. Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett. 176 (2008) 48-57
55. Ribeiro I.R., and Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars) 58 Suppl. 3 (1998) 50-53
56. Segditsas S., and Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25 (2006) 7531-7537
57. Li L.N., Zhang H.D., Yuan S.J., Tian Z.Y., Wang L., and Sun Z.X. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int. J. Cancer 121 (2007) 1360-1365
58. von Knethen A., and Brüne B. Attenuation of macrophage apoptosis by the cAMP-signalling system. Mol. Cell. Biochem. 212 (2000) 35-43